Glycation in Parkinson's disease and Alzheimer's disease

Hugo Vicente Miranda, Omar Ali El-Agnaf, Tiago Fleming Outeiro

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Glycation is a spontaneous age-dependent posttranslational modification that can impact the structure and function of several proteins. Interestingly, glycation can be detected at the periphery of Lewy bodies in the brain in Parkinson's disease. Moreover, α-synuclein can be glycated, at least under experimental conditions. In Alzheimer's disease, glycation of amyloid β peptide exacerbates its toxicity and contributes to neurodegeneration. Recent studies establish diabetes mellitus as a risk factor for several neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. However, the mechanisms underlying this connection remain unclear. We hypothesize that hyperglycemia might play an important role in the development of these disorders, possibly by also inducing protein glycation and thereby dysfunction, aggregation, and deposition. Here, we explore protein glycation as a common player in Parkinson's and Alzheimer's diseases and propose it may constitute a novel target for the development of strategies for neuroprotective therapeutic interventions.

Original languageEnglish
Pages (from-to)782-790
Number of pages9
JournalMovement Disorders
Volume31
Issue number6
DOIs
Publication statusPublished - 1 Jun 2016

Fingerprint

Parkinson Disease
Alzheimer Disease
Synucleins
Lewy Bodies
Proteins
Post Translational Protein Processing
Amyloid
Hyperglycemia
Neurodegenerative Diseases
Diabetes Mellitus
Peptides
Brain
Therapeutics

Keywords

  • Alzheimer's disease
  • Glycation
  • Neurodegenerative diseases
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Glycation in Parkinson's disease and Alzheimer's disease. / Vicente Miranda, Hugo; Ali El-Agnaf, Omar; Outeiro, Tiago Fleming.

In: Movement Disorders, Vol. 31, No. 6, 01.06.2016, p. 782-790.

Research output: Contribution to journalReview article

Vicente Miranda, Hugo ; Ali El-Agnaf, Omar ; Outeiro, Tiago Fleming. / Glycation in Parkinson's disease and Alzheimer's disease. In: Movement Disorders. 2016 ; Vol. 31, No. 6. pp. 782-790.
@article{e0e7f913a706448583aadd251f7a94a9,
title = "Glycation in Parkinson's disease and Alzheimer's disease",
abstract = "Glycation is a spontaneous age-dependent posttranslational modification that can impact the structure and function of several proteins. Interestingly, glycation can be detected at the periphery of Lewy bodies in the brain in Parkinson's disease. Moreover, α-synuclein can be glycated, at least under experimental conditions. In Alzheimer's disease, glycation of amyloid β peptide exacerbates its toxicity and contributes to neurodegeneration. Recent studies establish diabetes mellitus as a risk factor for several neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. However, the mechanisms underlying this connection remain unclear. We hypothesize that hyperglycemia might play an important role in the development of these disorders, possibly by also inducing protein glycation and thereby dysfunction, aggregation, and deposition. Here, we explore protein glycation as a common player in Parkinson's and Alzheimer's diseases and propose it may constitute a novel target for the development of strategies for neuroprotective therapeutic interventions.",
keywords = "Alzheimer's disease, Glycation, Neurodegenerative diseases, Parkinson's disease",
author = "{Vicente Miranda}, Hugo and {Ali El-Agnaf}, Omar and Outeiro, {Tiago Fleming}",
year = "2016",
month = "6",
day = "1",
doi = "10.1002/mds.26566",
language = "English",
volume = "31",
pages = "782--790",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Glycation in Parkinson's disease and Alzheimer's disease

AU - Vicente Miranda, Hugo

AU - Ali El-Agnaf, Omar

AU - Outeiro, Tiago Fleming

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Glycation is a spontaneous age-dependent posttranslational modification that can impact the structure and function of several proteins. Interestingly, glycation can be detected at the periphery of Lewy bodies in the brain in Parkinson's disease. Moreover, α-synuclein can be glycated, at least under experimental conditions. In Alzheimer's disease, glycation of amyloid β peptide exacerbates its toxicity and contributes to neurodegeneration. Recent studies establish diabetes mellitus as a risk factor for several neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. However, the mechanisms underlying this connection remain unclear. We hypothesize that hyperglycemia might play an important role in the development of these disorders, possibly by also inducing protein glycation and thereby dysfunction, aggregation, and deposition. Here, we explore protein glycation as a common player in Parkinson's and Alzheimer's diseases and propose it may constitute a novel target for the development of strategies for neuroprotective therapeutic interventions.

AB - Glycation is a spontaneous age-dependent posttranslational modification that can impact the structure and function of several proteins. Interestingly, glycation can be detected at the periphery of Lewy bodies in the brain in Parkinson's disease. Moreover, α-synuclein can be glycated, at least under experimental conditions. In Alzheimer's disease, glycation of amyloid β peptide exacerbates its toxicity and contributes to neurodegeneration. Recent studies establish diabetes mellitus as a risk factor for several neurodegenerative disorders, including Parkinson's and Alzheimer's diseases. However, the mechanisms underlying this connection remain unclear. We hypothesize that hyperglycemia might play an important role in the development of these disorders, possibly by also inducing protein glycation and thereby dysfunction, aggregation, and deposition. Here, we explore protein glycation as a common player in Parkinson's and Alzheimer's diseases and propose it may constitute a novel target for the development of strategies for neuroprotective therapeutic interventions.

KW - Alzheimer's disease

KW - Glycation

KW - Neurodegenerative diseases

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84959455993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959455993&partnerID=8YFLogxK

U2 - 10.1002/mds.26566

DO - 10.1002/mds.26566

M3 - Review article

VL - 31

SP - 782

EP - 790

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 6

ER -